NCT02701816Unknown不适用
Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Primary patency rate
研究概览
简要总结
- Prospective, single-arm, multi-center registry study
- A total of 150 subjects with femoropopliteal artery disease who meet all inclusion and exclusion criteria will be included.
- Patients will be followed clinically for 12 months after the procedure.
- Duplex ultrasound, CT or catheter-based angiography follow-up according to participating hospital's protocol will be performed at 12 months.
- Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12 months.
- Quality of life by standardized questionnaires (at baseline & at 1 & 12 months)
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 19 years of older
- •Symptomatic peripheral artery disease:
- •Moderate or severe claudication (Rutherford category 2 or 3)
- •Critical limb ischemia (Rutherford category 4-5)
- •Femoropopliteal artery lesions with stenosis > 50%
- •Patients with signed informed consent
排除标准
- •Acute critical limb ischemia
- •Severe critical limb ischemia (Rutherford category 6)
- •Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents
- •In-stent restenosis lesions (Restenosis lesions without previously implanted stents are eligible to the enrollment)
- •Bypass graft lesions
- •Age > 85 years
- •Severe hepatic dysfunction (> 3 times normal reference values)
- •Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
- •LVEF < 40% or clinically overt congestive heart failure
- •Pregnant women or women with potential childbearing
- •Life expectancy <1 year due to comorbidity
- •Untreated proximal inflow disease of the ipsilateral iliac arteries (more than 50% stenosis or occlusion)
结局指标
主要结局
Primary patency rate
时间窗: 12 months after the index procedure
Absence of restenosis \>50%
次要结局
- Target lesion revascularization rate(12 months)
- Stent fracture rate(12 months)
- Quality of life(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery DiseaseSymptomatic Peripheral Artery Disease With Femoropopliteal LesionsModerate or Severe Claudication (Rutherford Category 2 or 3)Critical Limb Ischemia (Rutherford Category 4 or 5)NCT06234280Yonsei University100
Unknown
不适用
Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)Symptomatic Peripheral Artery Disease With Femoropopliteal LesionsModerate or Severe Claudication (Rutherford Category 2 or 3)Critical Limb Ischemia (Rutherford Category 4 or 5)NCT03505931Yonsei University100
Unknown
不适用
Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)Iliac Artery DiseaseNCT02698358Yonsei University68
已完成
不适用
Korean Multicenter Registry of EPIC stent for Iliac Artery Disease: (K-EPIC Registry)KCT0002956Yonsei University Health System, Severance Hospital150
终止
4 期
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.AnemiaNCT00223938Sanofi112